LIU Xinpei, MIAO Qi, LIU Jianzhou. Potts Shunt for Refractory Pulmonary Hypertension: Historical and Future Perspectives[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 313-317. DOI: 10.12290/xhyxzz.2021-0047
Citation: LIU Xinpei, MIAO Qi, LIU Jianzhou. Potts Shunt for Refractory Pulmonary Hypertension: Historical and Future Perspectives[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 313-317. DOI: 10.12290/xhyxzz.2021-0047

Potts Shunt for Refractory Pulmonary Hypertension: Historical and Future Perspectives

More Information
  • Corresponding author:

    MIAO Qi  Tel: 86-10-69152829, E-mail: miaoqipumc@hotmail.com

  • Received Date: January 13, 2021
  • Accepted Date: March 22, 2021
  • Issue Publish Date: May 29, 2021
  • Pulmonary artery hypertension (PAH) is a disease secondary to congenital heart diseases, pulmonary vascular disorders, embolism, or idiopathic reasons. Surgery is necessary for PAH refractory to modern combined medical therapy. Results of lung transplantation are limited by factors like donor shortage, matching difficulty, immune rejection, etc. In order to make an extracardiac shunt to release the deadly right ventricular failure, the old Potts shunt surgery has enjoyed a recent revival. Although some early and mid-term results are satisfactory, the history of Potts shunt surgery in the treatment of refractory PAH is short and the sample size is limited. More proofs of medical research are needed for its specific indications, details of surgical strategies, and long-term prognosis. Based on its origin and development in the treatment of PAH, this paper reviews the advantages, future directions and unsolved key problems of Potts shunt surgery.
  • [1]
    Baruteau AE, Serraf A, Levy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results[J]. Ann Thorac Surg, 2012, 94: 817-824. DOI: 10.1016/j.athoracsur.2012.03.099
    [2]
    D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]. Ann Intern Med, 1991, 115: 343-349. DOI: 10.7326/0003-4819-115-5-343
    [3]
    Rossano JW, Singh TP, Cherikh WS, et al. The Interna-tional Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report-2019; Focus theme: Donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38: 1028-1041. DOI: 10.1016/j.healun.2019.08.002
    [4]
    Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. [J] Am J Cardiol, 1983, 51: 1560-1561. DOI: 10.1016/0002-9149(83)90678-1
    [5]
    Cantor WJ, Harrison DA, Moussadji JS, et al. Deter-minants of survival and length of survival in adults with Eisenmenger syndrome[J]. Am J Cardiol, 1999, 84: 677-681. DOI: 10.1016/S0002-9149(99)00415-4
    [6]
    Blanc J, Vouhe P, Bonnet D. Potts shunt in patients with pulmonary hypertension[J]. N Engl J Med, 2004, 350: 623. DOI: 10.1056/NEJM200402053500623
    [7]
    Baruteau AE, Belli E, Boudjemline Y, et al. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients[J]. Eur J Cardiothorac Surg, 2015, 47: e105-e110. DOI: 10.1093/ejcts/ezu445
    [8]
    Lancaster TS, Shahanavaz S, Balzer DT, et al. Midterm outcomes of the Potts shunt for pediatric pulmonary hyperten-sion, with comparison to lung transplant[J]. J Thorac Cardiovasc Surg, 2021, 161: 1139-1148. DOI: 10.1016/j.jtcvs.2020.10.163
    [9]
    Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT[J]. J Heart Lung Transplant, 2019, 38: 879-901. DOI: 10.1016/j.healun.2019.06.022
    [10]
    Thangappan K, Morales DLS. Commentary: To transplant or not to transplant: Potts shunt as an alternative to pediatric lung transplantation[J]. J Thorac Cardiovasc Surg, 2021, 161: 1149-1150. DOI: 10.1016/j.jtcvs.2020.11.062
    [11]
    Grady RM, Eghtesady P. Potts Shunt and Pediatric Pulmonary Hypertension: What We Have Learned[J]. Ann Thorac Surg, 2016, 101: 1539-1543. DOI: 10.1016/j.athoracsur.2015.08.068
    [12]
    Sabi TM, Schmitt B, Sigler M, et al. Transcatheter creation of an aortopulmonary shunt in an animal model[J]. Catheter Cardiovasc Interv, 2010, 75: 563-569. http://new.med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_JJ0217568038
    [13]
    Esch JJ, Shah PB, Cockrill BA, et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience[J]. J Heart Lung Transplant, 2013, 32: 381-387. DOI: 10.1016/j.healun.2013.01.1049
    [14]
    Boudjemline Y, Patel M, Malekzadeh-Milani S, et al. Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hyperten-sion: a case series[J]. Circ Cardiovasc Interv, 2013, 6: e18-e20.
    [15]
    Boudjemline Y, Sizarov A, Malekzadeh-Milani S, et al. Safety and Feasibility of the Transcatheter Approach to Create a Reverse Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension[J]. Can J Cardiol, 2017, 33: 1188-1196. DOI: 10.1016/j.cjca.2017.06.004
    [16]
    Ratnayaka K, Rogers T, Schenke WH, et al. Magnetic Resonance Imaging-Guided Transcatheter Cavopulmonary Shunt[J]. JACC Cardiovasc Interv, 2016, 9: 959-970. DOI: 10.1016/j.jcin.2016.01.032
    [17]
    Bui MT, Grollmus O, Ly M, et al. Surgical palliation of primary pulmonary arterial hypertension by a unidirectional valved Potts anastomosis in an animal model[J]. J Thorac Cardiovasc Surg, 2011, 142: 1223-1228. DOI: 10.1016/j.jtcvs.2010.10.060
    [18]
    Rosenzweig EB, Ankola A, Krishnan U, et al. A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: Early experience in adolescents and adults[J]. J Thorac Cardiovasc Surg, 2021, 161: 1438-1446. e2. DOI: 10.1016/j.jtcvs.2019.10.149
    [19]
    Garekar S, Meeran T, Dhake S, et al. Valved reverse Potts shunt in a case of pulmonary hypertension due to pulmonary veno-occlusive disease[J]. Indian J Thorac Cardiovasc Surg, 2021, 37: 89-92. DOI: 10.1007/s12055-020-00993-2
  • Related Articles

    [1]LI Shuting, DONG Lili, YANG Xinlei, LÜ Lin, LIU Fukai. Exploratory Study on the Impact of Intestinal Fungi on the Progression of Heart Failure in Patients with Chronic Kidney Disease[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2025-0016
    [2]TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594
    [3]XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. DOI: 10.12290/xhyxzz.2022-0440
    [4]QIU Luhong, LIU Yingxian, XU Xiqi. Nonnegligible Myocarditis: Insights from 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 530-534. DOI: 10.12290/xhyxzz.2022-0077
    [5]XU Fen, ZHOU Zhou. Universal Definition and Classification of Heart Failure Triggers the Standardization of Diagnosis and Treatment of Heart Failure[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 621-623. DOI: 10.12290/xhyxzz.2021-0436
    [6]QIN Yongwen, BAI Yuan. History and Development of Interventional Devices forCongenital Heart Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 309-312. DOI: 10.12290/xhyxzz.2021-0148
    [7]XIAO Jiawang, ZHU Xianyang. Evolution of Interventional Treatment of Congenital Heart Disease in China[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 303-308. DOI: 10.12290/xhyxzz.2021-0157
    [8]AI Shanshan, HE Aibin. Advances in Basic Research of Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 291-297. DOI: 10.12290/xhyxzz.2021-0055
    [9]ZHANG Hao, LI Shoujun, SU Zhanhao. Reflections on Improving the Diagnosis and Treatment of Congenital Heart Diseasein China: the Regionalization of Care for Congenital Heart Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 287-290. DOI: 10.12290/xhyxzz.20200280
    [10]Shuai HU, Zhi-yan HAN, Xiao-jian WANG, Jing-jun HAN, De-qiang WU, Lei ZHANG, Yan-gui LIN, Jian-wen LIANG, Wen-bin WEI, Wen-lin ZHANG, Cun-fu MU, Yi WANG, Dian-yuan LI. Monitoring Value of Central Venous Oxygen Saturation, the Substitute for Mixed Venous Oxygen Saturation, in Postoperative Care of Congenital Heart Disease with Pulmonary Arterial Hypertension:a Multicenter Prospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 228-233. DOI: 10.3969/j.issn.1674-9081.2018.03.008
  • Cited by

    Periodical cited type(5)

    1. 张东梅,黄玉葵,郑文金,詹凤丽,曾文振,周利锴. 南宁市围绝经期女性对围绝经期知识认知的现状调查. 中国妇幼保健. 2024(10): 1825-1828 .
    2. 史碧容,杨道秀,张辉,崔菊远,姚望,吴晓霞,廖小琴,杨长琼,孙晓莺. 恩施市基层医务人员对绝经及其治疗的认知现况调查与分析. 全科医学临床与教育. 2022(06): 552-554 .
    3. 丁鲡,谢莉玲,王富兰,周勤,孙文静. 临床护士围绝经期综合征风险预测模型的构建及验证. 护理研究. 2022(16): 2860-2866 .
    4. 丁鲡,谢莉玲,周勤. 不同等级医院护士围绝经期综合征现状调查及影响因素分析. 护理学杂志. 2022(20): 76-80 .
    5. 李阳美,陈怡帆,戴安琪,王佳茜,王春媛,李欣悦,曾婷婷,徐驰宇,黄娟,奚鑫,邹密,范尧,俞丽丽,周明芳,雷迅. 更年期“一日门诊”持续性综合管理参与者的真实体验研究. 全科护理. 2022(35): 5011-5014 .

    Other cited types(1)

Catalog

    Article Metrics

    Article views (1640) PDF downloads (184) Cited by(6)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close